<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00418951</url>
  </required_header>
  <id_info>
    <org_study_id>2006-0536</org_study_id>
    <nct_id>NCT00418951</nct_id>
  </id_info>
  <brief_title>Liposomal Amphotericin B (Ambisome) Versus Oral Voriconazole for the Prevention of Invasive Fungal Infections</brief_title>
  <official_title>Open, Randomized Comparative Trial of Two Different Schedules of Liposomal Amphotericin B Versus Oral Voriconazole for the Prevention of Invasive Fungal Infections</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>M.D. Anderson Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>M.D. Anderson Cancer Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal of this clinical research study is to compare the effectiveness of liposomal
      amphotericin B given three times per week , versus liposomal amphotericin B given once per
      week, versus oral voriconazole in the prevention of fungal infections in patients with acute
      myeloid leukemia (AML) or myelodysplastic syndromes MDS who are receiving chemotherapy. The
      safety of these treatments will also be studied and compared.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Ambisome and voriconazole are drugs that have been used to fight fungal infections, which
      typically occur during chemotherapy as a result of lowered immune system functioning.
      Ambisome works by binding to the sterol component of the fungal cell membrane. This causes
      &quot;holes&quot; to appear in the membrane, which leads to death of the fungal cell. Voriconazole
      inhibits an essential step of the biosynthesis of an important component of the fungal cell
      wall (ergosterol). This causes the impairment of the fungal cell wall.

      Before you can start treatment on this study, you will have &quot;screening tests.&quot; These tests
      will help the doctor decide if you are eligible to take part in this study. You will be asked
      questions about your medical history. You will have a complete physical exam and a chest
      x-ray. You will have computed tomography (CT) scans of the chest. You will also have about 1
      teaspoon of blood drawn for routine tests. Test results from the pregnancy test that you will
      have before your leukemia treatment will be looked at for this study. You will not have a
      pregnancy test performed for this study.

      If you are found to be eligible to take part in this study, you will be randomly assigned (as
      in the roll of dice) to one of 3 treatment groups (Group 1, Group 2, or Group 3).
      Participants in Groups 1 and 2 will receive treatment with ambisome. Participants in Group 3
      will receive treatment with voriconazole. Participants in all 3 groups will begin treatment
      24 hours after the last dose of chemotherapy.

      If you are assigned to Group 1, you will receive ambisome by vein as a continuous infusion
      over 2 hours 1 time per day, 3 times each week.

      If you are assigned to Group 2, you will receive ambisome by vein as a continuous infusion
      over 2 hours 1 time per week.

      If you are assigned to Group 3, you will take 2 pills by mouth (1 hour after breakfast) and 2
      pills by mouth (1 hour after dinner) for 1 day, which amounts to 4 pills in total on Day 1.
      You will then take 1 pill by mouth (1 hour after breakfast) and 1 pill by mouth (1 hour after
      dinner) everyday for the remainder of this study, which amounts to 2 pills in total each day.

      You will have about 1 teaspoon of blood drawn for routine tests 2 times each week. You will
      also receive treatment with standard of care medications. These medications (which will be
      specified by your doctor) will be used to help decrease the risk of developing bacterial
      infections and viral infections.

      If you develop a fever during treatment on this study, you will have a chest x-ray and a CT
      scan of the chest within 3 days after the fever started.

      You may remain on this study for up to 35 days (if you are receiving chemotherapy for the
      first time) and up to 42 days (if you have had prior chemotherapy). Your participation may
      end on this study if your study doctor thinks it is necessary, if other antifungal therapy is
      required, or if you develop any intolerable side effects.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2006</start_date>
  <completion_date type="Actual">October 2009</completion_date>
  <primary_completion_date type="Actual">October 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Invasive Fungal Infection</measure>
    <time_frame>35 days from the start of therapy for induction participants and 42 days for salvage participants.</time_frame>
    <description>Endpoint was whether participant had an invasive fungal infection or not, a potentially fatal complication with leukemia patients. Efficacy defined as absence of proven and probable fungal infection. Probable fungal infection is: 1) Positive radiographic findings consistent with fungal infections documented on CT imaging: Lower respiratory tract infection: halo sign, air crescent-sign, or cavity within areas of consolidation; Sinus: erosion of sinus walls or extension of infection to neighboring structures, extensive skull base destruction; and/or 2) Two positive galactomannan index test.</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">120</enrollment>
  <condition>Acute Myelogenous Leukemia</condition>
  <condition>Myelodysplastic Syndrome</condition>
  <arm_group>
    <arm_group_label>Liposomal amphotericin B: 3 mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>3 mg/kg intravenously (IV) three times per week</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Liposomal amphotericin B: 9 mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>9 mg/kg IV once per week</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Voriconazole: 400 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>400 mg oral twice daily day 1 followed by 200 mg twice daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Voriconazole</intervention_name>
    <description>400 mg by mouth twice daily on day 1, followed by 200 mg by mouth twice daily</description>
    <arm_group_label>Voriconazole: 400 mg</arm_group_label>
    <other_name>Vfend</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Liposomal amphotericin B</intervention_name>
    <description>3 mg/kg intravenously three times per week over 2 hours +/- 15 minutes</description>
    <arm_group_label>Liposomal amphotericin B: 3 mg/kg</arm_group_label>
    <other_name>Ambisome</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Liposomal amphotericin B</intervention_name>
    <description>9 mg/kg intravenously once per week over 2 hours +/- 15 minutes</description>
    <arm_group_label>Liposomal amphotericin B: 9 mg/kg</arm_group_label>
    <other_name>Ambisome</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of AML or high risk MDS undergoing induction chemotherapy or first salvage
             chemotherapy.

          -  Age &gt;/=18 years.

          -  Patients must sign an informed consent.

        Exclusion Criteria:

          -  Patients with history of anaphylaxis attributed to azole or amphotericin B compounds.

          -  Patients with clinical or other evidence that indicates that they have proven or
             probable invasive fungal infection prior to enrollment.

          -  Patients with total bilirubin levels &gt; 3 times the upper normal limits (i.e. &gt; 3.0
             mg/dl); or serum glutamic pyruvic transaminase (SGPT)&gt; 5 times upper limit normal.

          -  Patients with serum creatinine &gt; 2.0 mg/dl.

          -  Patients receiving any medication that is contraindicated with the use of
             voriconazole.

          -  Patients who have participated in this study during induction chemotherapy.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gloria N Mattiuzzi, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>M.D. Anderson Cancer Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Gloria N Mattiuzzi, MD</last_name>
    <role>Study Director</role>
    <affiliation>The University of Texas MD Anderson Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The University of Texas M D Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://mdanderson.org</url>
    <description>M.D. Anderson's website</description>
  </link>
  <verification_date>August 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 3, 2007</study_first_submitted>
  <study_first_submitted_qc>January 3, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 5, 2007</study_first_posted>
  <results_first_submitted>April 15, 2011</results_first_submitted>
  <results_first_submitted_qc>April 15, 2011</results_first_submitted_qc>
  <results_first_posted type="Estimate">May 13, 2011</results_first_posted>
  <last_update_submitted>August 1, 2012</last_update_submitted>
  <last_update_submitted_qc>August 1, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 7, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Voriconazole</keyword>
  <keyword>Vfend</keyword>
  <keyword>Liposomal amphotericin B</keyword>
  <keyword>Ambisome</keyword>
  <keyword>Acute Myelogenous Leukemia</keyword>
  <keyword>Myelodysplastic Syndrome</keyword>
  <keyword>AML</keyword>
  <keyword>MDS</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Preleukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
    <mesh_term>Mycoses</mesh_term>
    <mesh_term>Invasive Fungal Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Voriconazole</mesh_term>
    <mesh_term>Amphotericin B</mesh_term>
    <mesh_term>Liposomal amphotericin B</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Recruitment Period: 11/3/2006 to 8/4/09. All patients registered at The University of Texas M.D. Anderson Cancer Center.</recruitment_details>
      <pre_assignment_details>Eight of 120 patients registered never received study drug, therefore were excluded from the study.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Liposomal Amphotericin B: 3 mg/kg</title>
          <description>3 mg/kg intravenously (IV) three times per week</description>
        </group>
        <group group_id="P2">
          <title>Liposomal Amphotericin B: 9 mg/kg</title>
          <description>9 mg/kg IV once per week</description>
        </group>
        <group group_id="P3">
          <title>Voriconazole: 400 mg</title>
          <description>400 mg oral twice daily day 1 followed by 200 mg twice daily</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="39"/>
                <participants group_id="P2" count="33"/>
                <participants group_id="P3" count="40"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="39"/>
                <participants group_id="P2" count="33"/>
                <participants group_id="P3" count="40"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Liposomal Amphotericin B: 3 mg/kg</title>
          <description>3 mg/kg intravenously (IV) three times per week</description>
        </group>
        <group group_id="B2">
          <title>Liposomal Amphotericin B: 9 mg/kg</title>
          <description>9 mg/kg IV once per week</description>
        </group>
        <group group_id="B3">
          <title>Voriconazole: 400 mg</title>
          <description>400 mg oral twice daily day 1 followed by 200 mg twice daily</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="39"/>
            <count group_id="B2" value="33"/>
            <count group_id="B3" value="40"/>
            <count group_id="B4" value="112"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="60" lower_limit="25" upper_limit="84"/>
                    <measurement group_id="B2" value="71" lower_limit="23" upper_limit="78"/>
                    <measurement group_id="B3" value="71" lower_limit="19" upper_limit="80"/>
                    <measurement group_id="B4" value="60" lower_limit="19" upper_limit="84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="19"/>
                    <measurement group_id="B4" value="54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="21"/>
                    <measurement group_id="B4" value="58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="39"/>
                    <measurement group_id="B2" value="33"/>
                    <measurement group_id="B3" value="40"/>
                    <measurement group_id="B4" value="112"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Invasive Fungal Infection</title>
        <description>Endpoint was whether participant had an invasive fungal infection or not, a potentially fatal complication with leukemia patients. Efficacy defined as absence of proven and probable fungal infection. Probable fungal infection is: 1) Positive radiographic findings consistent with fungal infections documented on CT imaging: Lower respiratory tract infection: halo sign, air crescent-sign, or cavity within areas of consolidation; Sinus: erosion of sinus walls or extension of infection to neighboring structures, extensive skull base destruction; and/or 2) Two positive galactomannan index test.</description>
        <time_frame>35 days from the start of therapy for induction participants and 42 days for salvage participants.</time_frame>
        <population>Outcome evaluability required at least two doses of study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Liposomal Amphotericin B: 3 mg/kg</title>
            <description>3 mg/kg intravenously (IV) three times per week</description>
          </group>
          <group group_id="O2">
            <title>Liposomal Amphotericin B: 9 mg/kg</title>
            <description>9 mg/kg IV once per week</description>
          </group>
          <group group_id="O3">
            <title>Voriconazole: 400 mg</title>
            <description>400 mg oral twice daily day 1 followed by 200 mg twice daily</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Invasive Fungal Infection</title>
          <description>Endpoint was whether participant had an invasive fungal infection or not, a potentially fatal complication with leukemia patients. Efficacy defined as absence of proven and probable fungal infection. Probable fungal infection is: 1) Positive radiographic findings consistent with fungal infections documented on CT imaging: Lower respiratory tract infection: halo sign, air crescent-sign, or cavity within areas of consolidation; Sinus: erosion of sinus walls or extension of infection to neighboring structures, extensive skull base destruction; and/or 2) Two positive galactomannan index test.</description>
          <population>Outcome evaluability required at least two doses of study drug.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
                <count group_id="O2" value="28"/>
                <count group_id="O3" value="39"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Three years, ten months.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Liposomal Amphotericin B: 3 mg/kg</title>
          <description>3 mg/kg intravenously (IV) three times per week</description>
        </group>
        <group group_id="E2">
          <title>Liposomal Amphotericin B: 9 mg/kg</title>
          <description>9 mg/kg IV once per week</description>
        </group>
        <group group_id="E3">
          <title>Voriconazole: 400 mg</title>
          <description>400 mg oral twice daily day 1 followed by 200 mg twice daily</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="39"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="33"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Supravnetricular Tachycardia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="39"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Death</sub_title>
                <description>unrelated to study drug</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="39"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Allergic Reaction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Chest Pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperbilirubinemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Elevated alanine aminotransferase</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infection Sepsis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Acute Renal Failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Acute Respiratory Failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Jorge Cortes, MD / Professor</name_or_title>
      <organization>The University of Texas MD Anderson Cancer Center</organization>
      <phone>713-745-5783</phone>
      <email>eharrison@mdanderson.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

